Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Clinical trial NCT03232177 · COMPLETED

Trial details

NCT number: NCT03232177
Sponsor: Yuhan Corporation
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Essential Thrombocythemia

Start date: 2017-06-05
Primary completion: 2020-12-05
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.